180 related articles for article (PubMed ID: 38469984)
1. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE
Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984
[TBL] [Abstract][Full Text] [Related]
2. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
van der Made CI; Potjewijd J; Hoogstins A; Willems HPJ; Kwakernaak AJ; de Sevaux RGL; van Daele PLA; Simons A; Heijstek M; Beck DB; Netea MG; van Paassen P; Elizabeth Hak A; van der Veken LT; van Gijn ME; Hoischen A; van de Veerdonk FL; Leavis HL; Rutgers A
J Allergy Clin Immunol; 2022 Jan; 149(1):432-439.e4. PubMed ID: 34048852
[TBL] [Abstract][Full Text] [Related]
3. VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases.
Vitale A; Caggiano V; Bimonte A; Caroni F; Tosi GM; Fabbiani A; Renieri A; Bocchia M; Frediani B; Fabiani C; Cantarini L
Intern Emerg Med; 2023 Apr; 18(3):711-722. PubMed ID: 36662445
[TBL] [Abstract][Full Text] [Related]
4. VEXAS syndrome: A dermatological perspective.
Nguyen JK; Routledge D; van Der Weyden C; Blombery P; Angel CM; Johnson D; Goh MS; Lee A
Australas J Dermatol; 2022 Nov; 63(4):488-492. PubMed ID: 36197697
[TBL] [Abstract][Full Text] [Related]
5. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
7. UBA1 and DNMT3A mutations in VEXAS syndrome. A case report and literature review.
Shaukat F; Hart M; Burns T; Bansal P
Mod Rheumatol Case Rep; 2022 Jan; 6(1):134-139. PubMed ID: 34480172
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
Front Immunol; 2021; 12():800149. PubMed ID: 35126364
[TBL] [Abstract][Full Text] [Related]
9. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP; Hinojosa-Azaola A; Sánchez-Hernández BE; Crispín JC; Apodaca-Chávez E; Ferrada MA; Martín-Nares E
Reumatol Clin (Engl Ed); 2024 Jan; 20(1):47-56. PubMed ID: 38160120
[TBL] [Abstract][Full Text] [Related]
10. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
11. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome presenting as recurrent aseptic peritonitis in a patient receiving peritoneal dialysis: a case report.
Fukuda N; Kanai D; Hoshino K; Fukuda Y; Morita R; Ishikawa Y; Kanaoka T; Toya Y; Kirino Y; Wakui H; Tamura K
BMC Nephrol; 2024 Jan; 25(1):18. PubMed ID: 38212709
[TBL] [Abstract][Full Text] [Related]
12. [Macrocytic anemia and polychondritis: VEXAS syndrome].
Zeisbrich M; Schindler V; Krausz M; Proietti M; Mrovecova P; Voll RE; Glaser C; Röther F; Warnatz K; Venhoff N
Z Rheumatol; 2024 Apr; 83(3):229-233. PubMed ID: 36735069
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.
Kouranloo K; Dey M; Almutawa J; Myall N; Nune A
Rheumatol Int; 2023 Dec; ():. PubMed ID: 38129348
[TBL] [Abstract][Full Text] [Related]
14. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist.
Sterling D; Duncan ME; Philippidou M; Salisbury JR; Kulasekararaj AG; Basu TN
J Am Acad Dermatol; 2023 Dec; 89(6):1209-1214. PubMed ID: 35121074
[TBL] [Abstract][Full Text] [Related]
15. Clinical Challenges of Emerging Acquired Autoinflammatory Diseases, Including VEXAS Syndrome.
Kirino Y
Intern Med; 2024 Feb; ():. PubMed ID: 38296470
[TBL] [Abstract][Full Text] [Related]
16. VEXAS syndrome: a diagnostic puzzle.
Ruffer N; Krusche M
RMD Open; 2023 Aug; 9(3):. PubMed ID: 37532466
[TBL] [Abstract][Full Text] [Related]
17. An update on VEXAS syndrome.
Al-Hakim A; Savic S
Expert Rev Clin Immunol; 2023 Feb; 19(2):203-215. PubMed ID: 36537591
[TBL] [Abstract][Full Text] [Related]
18. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous vasculitis in autoinflammatory diseases.
Chen KR
J Dermatol; 2024 Feb; 51(2):150-159. PubMed ID: 37955334
[TBL] [Abstract][Full Text] [Related]
20. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
